Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices SynchroMax ET, Kalorama Information s Early Stage Drug Discovery 2004 ... Report, and Research and Markets Ion Channel Drug Discovery ... Report

Premium

Molecular Devices said last week that it has begun to ship the SynchroMax ET plate-handling robot, the latest addition to its line of microplate readers and liquid-handling systems.

According to the company, the SynchroMax ET provides walk-away automation for ELISA workstations and cell-based screening units that include the company’s SpectraMax or Gemini microplate reader, AquaMax dispenser, or Embla washer. Researchers can run up to 320 microplates in 96-, 384-, or 1,536-well formats.


Kalorama Information, a life sciences research provider, has released a new report entitled “Early Stage Drug Discovery 2004: Combi-chem and HTS Revisited.”

The report can be purchased for $2,995 at the following web address: http://www.kaloramainformation.com/pub/941708.html.


Research and Markets has announced the availability of its “Ion Channel Drug Discovery — Therapeutic Opportunities & Technology Progress” report.

The report identifies and analyzes advancements in ion-channel-targeted drug development and new technology. More information can be found at http://www.researchandmarkets.com/reports/c2822.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.